Dual-modal overcoming of physical barriers for improved photodynamic cancer therapy via soft organosilica nanocapsules Authors: Wei Lu, Yang Li, Xiaojun Zhang, Ning Wang, Dong Chen, Yatong Zhao, Guang Li, Xuzhi Shi, Xiaobo Ma, Xiaodan Su, Feng Wang, Chuqiang Shu, Kun Chen Published: 2024 ABSTRACT AbstractAmidst the burgeoning field of cancer nanomedicine, dense extracellular matrices and anomalous vascular structures in the tumor microenvironment (TME) present substantial physical barriers to effective therapeutic delivery. These physical barriers hinder the optimal bioavailability of nanomedicine. Here, we propose a pioneering dual-modal strategy for overcoming physical barriers via soft organosilica nanocapsules (SMONs). Hyaluronidase-modified flexible spheres work by degrading the extracellular matrix and utilizing their flexible characteristics to enhance penetration into deeper layers. Compared with their stiff counterparts, the SMONs show diminished Young’s modulus, then the inherent softness of the SMONs confers distinct advantages, and significantly augmented cellular internalization within 4T1 cells, leading to an amplified in vitro photodynamic therapeutic effect. Furthermore, hyaluronidase-functionalized SMONs (SMONs-HAase) exhibit enhanced tumor penetration in 3D spheroids. Post incorporation of the photosensitizer chlorin e6, when administered intravenously, these soft organosilica nanocapsules amplify the efficacy of photodynamic therapy. In addition, RNA-seq analysis of SMONs-HAase-Ce6 shows it alters gene expression, degrading the extracellular matrix and impairing mitochondrial function. To sum up, this work elucidates the potential of a dual-modal strategy, highlighting the promise of SMONs in overcoming TME physical barriers and optimizing therapeutic outcomes.Graphical abstract Supplementary InformationThe online version contains supplementary material available at 10.1186/s12951-024-02945-z.Keywords: Mesoporous organosilica, Soft nanoplatform, Tumor penetration, Photodynamic treatment Introduction Cancer nanomedicine has emerged at the forefront of therapeutic innovation, promising enhanced outcomes [1–3]. Yet, the entwined physical barriers in the intricate tumor microenvironment (TME) often challenge the effective deployment of these nanotherapeutics [4–6]. These physical barriers, such as a dense extracellular matrix, anomalous vascular structures, and escalated interstitial fluid pressure [7–9] collectively compromise the bioavailability, uniform distribution, and deep tissue penetration of the nanotherapeutics, thus attenuating their therapeutic potential. Given these obstacles, refining strategies to navigate the physical barriers in TME has attracted increased attention in nanomedicine [10]. One promising avenue lies in tailoring interventions to the TME’s inherent physical barriers [11–13]. For instance, matrix remodeling via enzymes such as collagenase could dismantle the extracellular matrix and thus pave the way for nanomedicine ingress [14–16]. Earlier studies illuminated that collagenase priming can boost nanoparticle uptake, especially in mammary tumors [17]. Furthermore, regulating tumor pressure with agents like hyaluronidase could offset the pronounced interstitial fluid pressure endemic to tumors, potentially fostering drug delivery of nanomedicines [18, 19]. However, mere tailoring interventions to the TME’s inherent physical barriers might only offer limited incremental advancements for nanomedicines. Emerging evidence alludes to the merit of adjusting the physicochemical attributes of nanomedicines. As a typical illustration, modulating nanoparticle size and morphology can dictate their in vivo behaviors [20–22]. Previously reported studies posited that diminutive nanoparticles with unique morphologies showcase enhanced tumor interstitial penetration and diffusion [23–26]. Moreover, surface modifications, such as PEGylation or specific targeting ligands, can not only circumvent immune surveillance but also heighten tumor cell affinity [27]. In addition, our exploration demonstrated the salient influence of the mechanical properties attributes of organosilica nanoparticles within the nano-biological interface [28]. Initial findings intimated that soft organosilica nanoparticles elevate cellular internalization, amass within tumors more proficiently, and potentiate photodynamic therapy outcomes. Thus, in this study, we present a dual-modal strategy to surmount physical barriers in the tumor microenvironment and thereby enhance the efficacy of photodynamic cancer therapy. This is achieved through the design and synthesis of soft organosilica nanocapsules (SMONs) modified with hyaluronidase. Notably, these engineered SMONs exhibit a significantly reduced Young’s modulus (89.6 ± 12.7 MPa), representing a 62% reduction relative to their rigid counterparts (144.15 ± 12.02 MPa). The inherent softness of the SMONs confers distinct advantages, and significantly augmented cellular internalization within 4T1 cells, leading to an amplified in vitro photodynamic therapeutic effect. To further advance their capability, we functionalized the SMONs with hyaluronidase, resulting in the derivative SMONs-HAase. Intriguingly, compared to both their rigid hyaluronidase-modified counterparts and the hyaluronidase-unmodified soft version, SMONs-HAase demonstrated markedly enhanced tumor penetration in 3D multicellular tumor spheroids in vitro. Building on the dual-modal barrier-bypassing prowess of SMONs-HAase, we proceeded to load them with the photosensitizer chlorin e6, yielding SMONs-HAase-Ce6. Remarkably, upon intravenous administration, this soft nano platform markedly amplified the therapeutic outcomes of photodynamic therapy. In addition, the investigation of SMONs-HAase-Ce6 through RNA-seq and subsequent analyses, including PCA, cluster analysis, KEGG, and GO, reveals substantial modulation of gene expression with up-regulation of extracellular matrix degradation and down-regulation of mitochondrial functions, suggesting impactful alterations in ECM and metabolic processes induced by SMONs-HAase-Ce6. In conclusion, our findings underscore the potential of a dual-modal approach to transcend physical barriers, heralding the evolution of nanotherapeutic platforms characterized by enhanced biological fidelity and amplified therapeutic efficacy. Materials and methods Materials The silica precursor tetraethyl orthosilicate (TEOS) and the cationic surfactant hexadecyltrimethyl ammonium bromide (CTAB) were procured from Sinopharm Chemical Reagent Co., Ltd., alongside NaOH, dioxane, and triphenylphosphine. Key organosilica crosslinker Bis[3-(triethoxysilyl) propyl] tetrasulfide (TESPTS), ethylenimine polymer (PEI), and the fluorophore fluorescein isothiocyanate (FITC), as well as hyaluronidase (HAase) and the photosensitizer Chlorin e6 (Ce6), were obtained from Sigma-Aldrich. For pH adjustment and reaction mediums, a concentrated ammonia solution, anhydrous ethanol, and N, N-dimethylformamide (DMF) were acquired from Nanjing Chemical Reagent Co., Ltd. Sinopharm also supplied the essential reagents hydrochloric acid and glutaraldehyde. N-hydroxysulfosuccinimide (NHS) was secured from Shanghai Aladdin Bio-Chem Technology Co., LTD. The Millipore system provided deionized water with a resistivity of 18 MΩ·cm− 1 for all experimental processes. Cell culture and apoptosis assays were conducted using materials from Nanjing Keygen Biotech, including Dulbecco’s Modified Eagle Medium (DMEM), phosphate-buffered saline (PBS), 4’-6-diamidino-2-phenylindole (DAPI), and an Annexin V-FITC/PI apoptosis detection kit. The cell viability assay utilized a CCK-8 kit from Biosharp Co., Ltd. Fetal bovine serum (FBS) for cell culture was sourced from Gibco Laboratories. The murine breast cancer cell line 4T1 was supplied by the American Type Culture Collection (ATCC). Organosilica nanoplatform construction The fabrication of thioether-bridged mesoporous organosilica nanoparticles (MONs) commenced with the preparation of a homogenous mixture composed of CTAB (0.16 g), ethanol (30 mL), distilled water (75 mL), and concentrated ammonium hydroxide solution (1.0 mL, 25–28 wt %). To this solution, organosilica precursors, precisely 0.1 mL of TESPTS and 0.25 mL of TEOS, were rapidly introduced. The resultant mixture was subjected to continuous stirring at 35 °C for 24 h. After the reaction period, the formed MONs were segregated via centrifugation and subjected to triple washing with ethanol to remove impurities. To extract the residual surfactant from the nanoparticles, the MONs were redispersed in a 200 mL ethanol solution, acidified with 400 µL of concentrated hydrochloric acid. The dispersion was then stirred at a speed of 500 rpm within a 60 °C water bath for 3 h, a process which was methodically repeated thrice to ensure thorough surfactant removal. The resulting nanoparticles were further purified with two additional rounds of washing using ethanol followed by water. The purified MONs were finally redispersed in 30 mL of water, rendering them suitable for subsequent experimental utilization. The careful control of synthesis conditions and rigorous purification ensured the high quality and functional integrity of the nanoparticles. Preparation of soft MONs (SMONs) The synthesis of soft MONs (SMONs) was achieved by employing a preferential etching technique utilizing NaOH, as delineated in prior studies [18]. In this method, 50 mg of pre-synthesized MONs were uniformly dispersed in 25 mL of 0.1 M NaOH aqueous solution and allowed to interact for 5 min, a time frame optimized to yield the desired nanoparticle softness and porosity without compromising structural integrity. After etching, the particles were isolated by centrifugation at 10,000 rpm for 10 min. To ensure the complete removal of alkaline residues, the harvested SMONs underwent a rigorous washing protocol with deionized water, repeated thrice. The washed nanoparticles were then redispersed in 10 mL of water, rendering them apt for further experimentation. This procedure, underpinned by its simplicity and efficacy, affirms the feasibility of the SMONs fabrication for following biomedical applications. Modification of HAase and Ce6 Surface modification of SMONs was accomplished through a PEI-assisted cross-linking procedure. Initially, 10 mg of SMONs were introduced into a 20 mL PEI solution (1 mg·mL− 1) and the suspension was left undisturbed for 20 min to facilitate adequate surface binding. Following this, the nanoparticles underwent thrice-repeated water wash to remove unbound PEI, yielding PEI-modified SMONs (SMONs-PEI). The SMONs-PEI were then subjected to further modification by the addition of 5 mL of glutaraldehyde (GA, 25 wt%) solution, and the mixture was agitated at ambient temperature for 12 h. Successive washing with deionized water three times ensured the removal of excess GA, after which the nanoparticles were dispersed in 10 mL of water to acquire the SMONs-PEI-GA solution. Enzymatic functionalization was conducted by introducing 10 mL of a HAase solution (0.5 mg·mL− 1) to the SMONs-PEI-GA suspension, and the amalgamation was incubated with agitation for another 12 h, resulting in SMONs-HAase. Simultaneously, the carboxyl groups of Chlorin e6 (Ce6) were activated for subsequent conjugation. A mixture of Ce6 (20 mg), NHS (10 mg), and EDC (10 mg) was prepared in 12 mL of DMF and shaken in darkness for 12 h, culminating in carboxyl-activated Ce6. The final conjugation step involved the addition of 2 mg of activated Ce6 to the SMONs-HAase suspension, followed by a 12-hour incubation in darkness with agitation. Post-incubation, the nanoparticles were washed thrice with deionized water and redispersed in 10 mL of water, resulting in the formation of HAase and Ce6-loaded soft MONs (SMONs-HAase-Ce6), poised for investigative applications. Cytotoxicity assay and hemolysis HUVECs, MDA-MB-231, and 4T1 Cells were cultured in a 96-well plate (100 µL, 1 × 104 cells per well) by using Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS). The cells were incubated at 37 °C for a period of 12 h to allow for adherence and stabilization. Post-incubation, the supernatant was carefully aspirated, and the cells were exposed to varied concentrations of MONs-HAase-Ce6 (0, 50, 100, 200 µg·mL− 1) across a temporal gradient of 24, 48, and 72 h, assigning five replicate wells for each dosage. Following the exposure period, cell viability was assessed by adding 10 µL of CCK-8 solution to each well, with a subsequent incubation of 1 h to permit sufficient interaction. To account for the inherent fluorescence absorbance by the nanomaterials, MONs-HAase-Ce6 was also introduced into wells devoid of cells, mirroring the concentrations and volumes applied to the test wells, and serving as a background control. This methodology ensures a rigorous quantitative analysis of cellular response to the nanoparticle treatment. Finally, the absorbance was recorded at 450 nm using an M200 PRO microplate reader. The viability of 4T1 cells (CV) was calculated as follows: . The subsequent cell culture protocol followed the previously described method. The selected cells included HUVECs, MDA-MB-231, 4T1, and Mouse Colorectal Carcinoma Cells (CT26). The incubation time for SMONs-HAase-Ce6 was either 24–48 h. The absorbance at 450 nm was measured using a multifunctional enzyme marker. Red blood cells (RBCs) were isolated by centrifuging 1 mL of blood at 2000 rpm for 5 min. The collected RBCs were then suspended in 2 mL of phosphate-buffered saline (PBS) solution. A 0.2 mL suspension of RBCs in physiological saline was taken and mixed with 0.8 mL of MONs-HAase-Ce6 or SMONs-HAase-Ce6 (25, 50, 100, 200, 400 µg·mL− 1). The mixture was incubated for 4 h. As a positive/negative control, an equal amount of RBCs were suspended in a mixture of H2O or PBS. After the incubation, the mixture was centrifuged, and the supernatant was collected. The absorbance at 416 nm was measured, and the hemolysis(H)was calculated by the following formula: . Cellular uptake assessment in vitro Mouse Breast Carcinoma Cells (4T1) were cultured in a confocal dish and incubated at 37 °C for a duration of 12 h. Subsequently, the medium was exchanged for a fresh medium augmented with MONs-HAase-Ce6, SMONs-Ce6, and SMONs-HAase-Ce6, each at a concentration equivalent to 3.0 µg·mL− 1 of Ce6. After a further incubation of 6 h, cells were fixed using 4% paraformaldehyde for 20 min. Nuclei were then stained with DAPI Staining Solution, and confocal laser scanning microscopy (CLSM) was employed to ascertain the distribution of the nuclei (blue fluorescence) and intracellular Ce6 (red fluorescence). Fluorescence intensity was quantified utilizing Image J software. Moreover, the cellular internalization of HAase-loaded nanoparticles was quantified via flow cytometry. To this end, 4T1 cells were incubated with each nanoparticle formulation for 1, 3, and 6-hour intervals. After triple PBS washes, the cells were enzymatically dissociated and resuspended in 200 µL of PBS. The degree of nanoparticle uptake was then quantified through flow cytometric analysis. Penetration in 4T1 tumor spheroids The permeation efficacy of SMONs-HAase-Ce6 was assessed using three-dimensional multicellular tumor spheroids. An initial step involved dissolving 0.16 g of agarose in 10 mL of DMEM medium, which was then heated and stirred at 100 °C until fully dissolved. Each well of a 96-well plate was then coated with 100 µL of this agarose solution and allowed to solidify to form a non-adherent surface. Subsequently, 4T1 mouse breast carcinoma cells were seeded into these wells at a density of 1 × 104 cells per well. The cells were cultured for 7 days to facilitate the formation of cohesive tumor spheroids. Following spheroid formation, the experimental groups, namely MONs-HAase-Ce6, SMONs-Ce6, and SMONs-HAase-Ce6, were introduced into the respective wells and co-cultured for 12 h. The distribution and penetration of the nanoparticles within the tumor spheroids were then visualized using confocal microscopy. This method allows for the detailed observation of nanoparticle dynamics in a simulated tumor microenvironment, highlighting their potential for enhanced delivery in therapeutic applications. In vitro PDT 4T1 cells were initially seeded at a density of 1 × 104 cells per well in a 96-well plate and incubated for 24 h. Subsequently, the cells were treated with MONs-HAase-Ce6, SMONs-Ce6, and SMONs-HAase-Ce6 at varying concentrations (0, 0.2, 0.5, 1.0, 2.0, 3.0 µg·mL− 1, based on Ce6 concentration) for an additional 24-hour period. Post-treatment, cells were washed twice with PBS and then exposed to 660 nm laser irradiation at a power density of 1 W·cm− 2 for 3 min. Cell viability was assessed by adding 10 µL of CCK-8 solution to each well and incubating for 1 h, with absorbance subsequently measured at 450 nm using a multifunctional microplate reader. Additionally, the Calcein/PI cell viability/cytotoxicity assay was utilized to determine the viability and cytotoxicity of 4T1 cells. Cells were plated in confocal dishes at a density of 1 × 104 cells per dish and incubated for 12 h before replacing the medium with fresh DMEM containing the same nanoparticle formulations. After 12 h of further incubation and two PBS washes, cells were irradiated with a 660 nm laser for 3 min at a power density of 1 W·cm− 2. Confocal microscopy was employed to visualize live and dead cells, providing insight into the distribution of viable and non-viable cells. For apoptosis analysis, 4T1 cells were seeded at 1 × 105 cells per well in 6-well plates and cultured for 24 h before the nanoparticle treatments. After 12 additional hours and PBS washes, cells were exposed to 660 nm laser irradiation for 5 minutes at the same power density. Following 12 h of co-culture, cells were stained with Annexin V-FITC and PI and analyzed via flow cytometry to quantify apoptosis. Lastly, to assess reactive oxygen species (ROS) generation, 4T1 cells were inoculated onto confocal dishes and incubated for 12 h before being treated with the nanoparticles. After an additional 12-hour incubation and laser irradiation for 3 min, cells were stained with the ROS-sensitive dye DCFH-DA for 30 min. The generation of ROS was then visualized using confocal fluorescence microscopy and quantified by flow cytometry, providing comprehensive insights into oxidative stress induced by the nanoparticle treatments. Tumor xenograft model Animal studies reported herein adhered to protocols rigorously reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) at the Medical School of Nanjing University. Female BALB/c mice, aged four to five weeks, were procured from the Yangzhou Laboratory Animal Center, China. To establish a breast cancer model, each mouse received a subcutaneous injection of 5 × 106 4T1 cells into the fourth mammary fat pad. Tumor volumes were monitored bi-daily, and in vivo experiments were conducted until tumors attained a volume range of 150–200 mm3. This approach ensured the maintenance of ethical standards while providing a reliable model for evaluating cancer progression and therapeutic efficacy. In vivo anti-tumor effect In this study, 4T1 tumor-bearing BALB/c mice (n ≥ 5 per group) were allocated into four distinct groups: (i) PBS control, (ii) MONs-HAase-Ce6, (iii) SMONs-Ce6, and (iv) SMONs-HAase-Ce6. Each group received an intravenous injection of 100 µL of the respective formulations, with the dosage of Ce6 approximating 2.5 mg·kg− 1, except for the PBS group. Twenty-four hours post-injection, the tumors were subjected to laser irradiation at 660 nm and 1 W·cm− 2 for 5 min, covering the entire tumor area. Following irradiation, body weight, and tumor volumes were meticulously recorded over a consecutive 14-day period. Tumor volume was calculated using the formula: V = Width2 × length / 2. On the final day of the study, the mice were euthanized, and the tumors were excised, weighed, and photographed for further analysis. Tissues, including tumors and major organs (heart, liver, spleen, lung, and kidney), were harvested, fixed in 4% paraformaldehyde, and embedded in paraffin. Tissue sections were stained with hematoxylin and eosin (H&E) and examined under an optical microscope to assess the therapeutic efficacy of the treatments. This comprehensive evaluation provided insights into the potential of each nanoparticle formulation in mitigating tumor growth and its systemic effects. In vivo toxicity Healthy female Balb/c mice were allocated into four groups (six mice per group) and subjected to the same experimental regimen as employed in the in vivo anti-tumor efficacy study. Following 14 days, the mice were euthanized, and comprehensive evaluations were conducted to assess hematological, biochemical, and histological parameters. Blood samples were meticulously collected from the orbital sinus and immediately stored in 200 µL heparinized Eppendorf tubes. These samples were maintained at 4 ℃ overnight to stabilize the blood constituents. Subsequently, the samples were centrifuged, and the serum was harvested for the analysis of various biochemical markers. Post-sacrifice, histological examinations were performed on paraffin-embedded tissue sections of critical organs. These sections were stained with hematoxylin and eosin (H&E) and meticulously examined under a microscope to identify any histopathological alterations such as lipid degeneration, edema, or necrosis. This thorough histological assessment aimed to elucidate the systemic impact of the administered treatments on the integrity and function of vital organs. Characterization Transmission electron microscopy (TEM) analyses were conducted using a Hitachi HT7700 microscope (Tokyo, Japan) at an accelerating voltage of 100 kV. Complementary elemental mapping and high-resolution TEM (HR-TEM) studies were performed on an FEI Talos F200X electron microscope equipped with an energy-dispersive X-ray (EDX) detector, facilitating detailed atomic-level imaging and compositional analysis. Scanning electron microscopy (SEM) was carried out using a Hitachi S4800 microscope (Tokyo, Japan) at a reduced voltage of 5 kV to prevent electron beam-induced damage while capturing high-resolution surface morphology. The hydrodynamic size and zeta potential of the nanoparticles were determined using a Brookhaven Zeta PALS analyzer (Brookhaven Instruments Co., Holtsville, USA), ensuring accurate characterization of particle stability and surface charge in colloidal dispersions. Fourier Transform Infrared (FT-IR) spectra were obtained with a NEXUS 870 spectrometer (Nicolet Instruments Inc., Madison, WI, USA), using KBr pellets to assess the chemical functionalities present in the solid samples. The mechanical properties, specifically Young’s modulus of the samples, were quantitatively measured using Atomic Force Microscopy (AFM) in the Peak Force Quantitative Nanomechanical Mapping mode (PeakForce QNM, Dimension Icon AFM, Bruker, USA). Measurements were performed with a TESPA-V2 AFM cantilever (Bruker AFM probes), and samples were prepared by depositing a drop of aqueous suspension onto a freshly cleaned silica surface (18.2 MΩ·cm− 1, Millipore, Merk Australia). Young’s modulus values were derived from the linear portion of the retraction curve using the Hertzian contact mechanics model. Finally, fluorescence intensities of the samples were recorded using an Infinite M200 PRO microplate reader (Tecan, Switzerland), which provided sensitive and quantitative fluorescence detection necessary for evaluating the optical properties of the samples. These comprehensive characterizations underscored the multifaceted analytical approach required to elucidate the structural and functional attributes of the nanoparticles. Colony formation assay Cells harvested from culture flasks were subjected to enzymatic digestion using trypsin, followed by separation via centrifugation. The resultant cell pellet was resuspended in DMEM supplemented with 10% FBS to prepare a homogeneous cell suspension. After counting, the cells were diluted to a concentration of 1 × 103 cells·mL− 1. These cells were then plated at a density of 200 cells per well in a six-well plate, with each well containing 3 mL of the medium. The cultures were maintained for 5 days to allow colony formation. Upon the visible appearance of colonies, the cell culturing was terminated. Each well was washed with PBS, fixed with methanol, and stained for 5 min using either 0.1% crystal violet or Giemsa stain. Following staining, optical images of the colonies were captured for further analysis. This method facilitated the evaluation of cellular proliferation and clonogenic capacity under defined experimental conditions. Statistical analysis Experimental results were expressed as the mean ± standard deviation. Student’s t-test was performed for comparing data with two groups and variance (ANOVA) test was performed when multiple groups were compared. P < 0.05 was considered statistically significant (GraphPad Software Inc., CA, USA). Results and discussion Figure 1A depicts the preparation of the pliable SMONs-HAase via a targeted etching method in an aqueous sodium hydroxide (NaOH) solution. Thioether-bridged mesoporous organic-inorganic silica nanoparticles (MONs) were synthesized using a sol-gel method. Cetyltrimethylammonium bromide (CTAB) served as a template, while tetraethyl orthosilicate (TEOS) and triethoxy(thiethyl)silane (TETS) acted as silica sources. This approach ensured the formation of a mesoporous structure tailored for advanced biomedical applications. TEM images show that the MONs exhibit uniform size, good dispersity, and typical spherical morphology (Fig. S1). Subsequently, sodium hydroxide was employed to create flexible mesoporous organic-inorganic silica nanoparticles (SMONs). To enable efficient loading of HAase and Ce6, polyethyleneimine (PEI) was initially electrostatically adsorbed onto the surface of SMONs, followed by an amidation reaction to ensure high loading capacity of HAase and Ce6 onto the SMONs (Fig. 1A). The concept of enhancing tumor penetration in cancer PDT of SMONs-HAase-Ce6. (A) Schematic illustration of matrix-degrading soft MONs-HAase-Ce6 nano-particles simultaneously enhances the penetration and cellular uptake of nano-particles deep into tumor tissues to effectively inhibit cancer growth. (B) TEM images of the SMONS-HAase-Ce6. (C) High-magnification TEM images of the SMONS-HAase-Ce6. (D) SEM images of the SMONS-HAase-Ce6 The transmission electron microscope (TEM) images reveal that the SMONs-HAase-Ce6 remains a uniform size and good dispersibility. Notably, the nanoparticles exhibit a distinctive collapsed, hollow structure with cross-folded wrinkles, resembling a “deflated balloon” (Fig. 1B-C). Scanning electron microscopy (SEM) analysis corroborates the uniformly crinkled surface texture and the exceptionally thin exterior of the SMONs-HAase-Ce6, as demonstrated in Fig. 1D. The element mapping results indicate that C, Si, N, and O are uniformly distributed on the layer of the nanoparticles, further demonstrating the formation of the hollow structure (Fig. 2A). The SMONs-HAase-Ce6 exhibit dimensions with an average diameter of 218 nm, an internal cavity approximately 201 nm wide, and a shell thickness around 12 nm (Fig. S3). The results indicated that MONs exhibited uniform and regular spherical morphology, while SMONs presented an irregular and collapsed morphology with wrinkled and sunken surfaces, consistent with the electron microscopy observations (Figs. 1B-D and 2B and C and S1). Then, the mechanical properties of MONs-HAase-Ce6 and SMONs-HAase-Ce6 in water were investigated using AFM. The SMONs show an elastic Young’s modulus (EY) of 89.6 ± 12.7 MPa, significantly lower than that of rigid MONs (144.15 ± 12.02 MPa), indicating that SMONs are characterized by lower hardness and flexible skeleton structure (Fig. 2D). These observations suggest that the SMONs maintained their structural flexibility in aqueous solution. Then, polyethyleneimine (PEI) was adsorbed onto the surface of SMONs through electrostatic interactions. The amino and aldehyde groups of PEI then reacted with glutaraldehyde (GA) to form linkages. Subsequently, the aldehyde groups of GA bound to adhesive proteins like hyaluronidase (HAase) at one end, which in turn attach to Ce6 through amide reactions at the other end. The measured zeta potentials of SMONs, SMONs-PEI, SMONs-PEI-GA, SMONs-HAase, and SMON-HAase-Ce6 were − 25.44 ± 0.75 mV, 56.80 ± 2.46 mV, 32.71 ± 2.26 mV, 13.13 ± 0.24 mV, and − 33.83 ± 0.24 mV, respectively (Fig. 2E). In addition, dynamic light scattering (DLS) results showed that the hydrodynamic diameter of the SMONs, SMONs-HAase, and SMONs-HAase-Ce6 was 230 nm, 286 nm, and 327 nm, respectively, indicating the relatively good solution stability and dispersion (Fig. 2F and S2A). The DLS and SEM images of MONs, MONs-HAase, and MONs-HAase-Ce6 showed that the size change trends upon conjugation with HAase and Ce6 are consistent with that of SMONs (Fig. S1 and S2B-D). (A) The STEM-HAADF imagery, along with EDX elemental mapping visuals and the associated composite image, delineates the composition of the SMONs-HAase-Ce6. (B-C) AFM images of MONs (left) and SMONs (right). (D) The Young’s modulus data of MONs and SMONs (*p < 0.05). (E) Zeta potential of SMONs, SMONs-PEI, SMONs-PEI-GA, SMONs-HAase, and SMONs- HAase-Ce6. (F) Dynamic light scattering of SMONs, SMONs-HAase, SMONs-HAase-Ce6. (G) FTIR spectrum of SMONs, HAase and SMONs-HAase-Ce6. (H) Diagram of Ce6 loading in SMONS-HAase. (I) UV-vis spectrum of Ce6, SMONs, SMONs-HAase-Ce6 Furthermore, the data of Fourier Transform Infrared Spectroscopy (FT-IR) showed a peak at 1610 cm− 1, corresponding to the carboxylic acid stretching vibration of HAase, confirming the successful loading of HAase onto SMONs (Fig. 2G). The cartoon diagram illustrates the loading strategy of the Ce6 on the SMONs-HAase (Fig. 2H). UV-vis spectroscopy showed two absorption peaks at around 660 nm and 400 nm for SMONs-HAase-Ce6, which were consistent with the characteristic absorption peaks of Ce6, indicating successful loading of Ce6 (Fig. 2I). Furthermore, it was calculated that the Ce6 loading capacity of SMONs-HAase-Ce6 (115.4 µg/mg) was higher compared to MONs-HAase-Ce6 (45.73 µg/mg) and SMONs-Ce6 (56.58 µg/mg). Next, the in vitro biosafety of MONs-HAase-Ce6 and SMONs-HAase-Ce6 was first investigated without NIR irradiation. (Fig. 3). The SMONs-HAase-Ce6 nanoparticles showed no significant differences in cell viability when incubated with HUVECs, MDA-MB-231, and 4T1 cells at different concentrations (Fig. 3A-C). The results indicated that all groups held relatively high cell viability over 80% at concentrations up to 200 µg·mL⁻¹ after being cultured for 24, 48, and 72 h. We then assessed the in vitro biosafety of SMONs-HAase-Ce6 that co-incubated with HUVEC, MDA-MB-231, 4T1, and Mouse Colorectal Carcinoma Cells (CT26) for 24 h and 48 h. The relative cell viability remained at 86% at various cells(at 200 µg·mL− 1)as assessed via CCK-8 assay (Fig. 3D). In vitro biocompatibility of MONs-HAase-Ce6 and SMONs-HAase-Ce6 nanoparticles. (A-C) Cytotoxicity of SMONs-HAase-Ce6 in HUVECs (Brown), MDA-MB-231(Purple), and 4T1 cells (Red), respectively, for 24, 48, and 72 h (n = 3, means ± SD). (D) The comparative cytotoxicity of SMONs-HAase-Ce6 in HUVECs, MDA-MB-231, 4T1, and CT26 cells for 24, and 48 h (200 µg·mL− 1, the blue indicates cell groups incubated with PBS, and the brown indicates cell groups incubated with SMONs-HAase-Ce6) (E-F) Hemocompatibility of MONs-HAase-Ce6 and SMONs-HAase-Ce6 nanoparticles To investigate the hemocompatibility of nanocarriers, the hemolysis of red blood cells (RBCs) was analyzed following treatment with SMONs-HAase-Ce6 and MONs-HAase-Ce6. Hemolysis of red blood cells (RBCs) leads to the release of hemoglobin, which manifests as a pronounced absorbance at 416 nm in the supernatant. Notably, no obvious hemoglobin release was observed even across varying concentrations of MONs-HAase-Ce6 and SMONs-HAase-Ce6 in contrast with the positive control groups using H2O (Fig. 3E). In the presented analysis, it was demonstrated that the hemolytic activity of SMONs-HAase-Ce6 and MONs-HAase-Ce6 on red blood cells (RBCs) exhibited a pronounced concentration-dependent trait. Importantly, within the concentration range of 0 to 400 µg·mL− 1, the rate of hemolysis was consistently maintained at a low level (below 4%) as shown in Fig. 3F. These data suggest the absence of significant cytotoxic effects of SMONs-HAase-Ce6 or MONs-HAase-Ce6 on RBCs, as illustrated in Fig. 3E-F, indicating their potential biocompatibility. In the subsequent analysis, 4T1 tumor cells were utilized to assess the cellular uptake of SMONs-HAase-Ce6 and MONs-HAase-Ce6, as illustrated in Fig. 4. Confocal laser scanning microscopy (CLSM) imagery revealed a marked augmentation in fluorescence intensity for the cohort treated with SMONs-HAase-Ce6 (see Fig. 4A). Quantitatively, the intracellular Ce6 fluorescence within the SMONs-HAase-Ce6 treated cells was approximately double that observed in the MONs-HAase-Ce6 group. This enhanced cellular uptake was further validated quantitatively through flow cytometry, which demonstrated a progressive increment in fluorescence intensity correlating with incubation durations spanning from 1 to 6 h. This increment denotes a time-dependent uptake characteristic of the nanomedicine. Intriguingly, the relative mean fluorescence intensities in the cohort treated with SMONs-HAase-Ce6 exhibited an approximate 2-fold augmentation as juxtaposed with the rigid MONs-HAase-Ce6 group (Fig. 4B-E). These observations compellingly substantiate that flexible SMONs-HAase-Ce6 nanoplatforms demonstrate superior internalization efficiency within 4T1 cells in comparison to their rigid counterparts. The inherent deformability of soft nanoparticles is hypothesized to reduce the invagination of cellular membranes, thereby preserving energy during the internalization process that is essential for nanoparticle envelopment. Cellular uptake and osmosis of SMONs-HAase-Ce6. (A) Fluorescence images of 4T1 cells incubated with MONs-HAase-Ce6 and SMONs-HAase-Ce6 for 6 h (scale: 50 μm). (B-E) Flow cytometry and relative fluorescence intensity of 4T1 cells incubated with the MONs-HAase-Ce6 and SMONs-HAase-Ce6 for 1, 3, and 6 h. (F) CLSM Z-stack scanning images of multicellular spheroids incubated with the MONs-HAase-Ce6, SMONs-Ce6, and SMONs-HAase-Ce6 (scale: 100 μm). (G-I) Surface plot images of multicellular spheroids along the arrow region at the Z-axis distance of 100 μm incubated with the SMONs-HAase-Ce6, MONs-HAase-Ce6, and SMONs-Ce6, respectively. (J) Schematic illustration of multicellular spheroids incubated with MONs-HAase-Ce6, SMONs-Ce6, and SMONs-HAase-Ce6 Otherwise, in the context of the tumor microenvironment, hyaluronic acid (HA)—a principal component of the extracellular matrix (ECM)—is selectively degraded by hyaluronidase (HAase). This enzymatic action leads to a loosening of the ECM structure, which in turn facilitates deeper drug penetration into tumor tissues. Thus, we also utilized multicellular spheroids (MCSs) originating from 4T1 cells as in vitro three-dimensional (3D) models to examine the tumor penetration efficiency of SMONs-HAase-Ce6 by utilizing CLSM along the Z-axis. The surface at the top of the spheroid was defined as 0 μm. The CLSM images from 20 to 160 μm depth were tomography, as shown in Fig. 4F. Results showed that compared with the MONs-HAase-Ce6 group, the SMONs-Ce6 and SMONs-HAase-Ce6 groups exhibited stronger fluorescence intensity, indicating that nanocarriers with flexible hollow structures can more easily penetrate the deep regions of the spheroids. Meanwhile, compared with the SMONs-Ce6 group, the fluorescence halo of the SMONs-HAase-Ce6 group was closer to the center of the spheroids, indicating that HAase played a role in degrading the matrix during particle penetration, enabling the flexible nanocarriers loaded with HAase (SMONs-HAase-Ce6) to infiltrate further into the depths of the tumor. For a lateral comparison, the CLSM image at 100 μm was selected. Surface plots were generated from the fluorescent images using ImageJ software (Fig. 4G-I). The image showed that in the central region of the spheroids, from 20 μm to 160 μm, the SMONs-HAase-Ce6 group exhibited the highest grayscale fluorescence intensity compared to the SMONs-Ce6 and MONs-HAase-Ce6, with the widest distribution. These results further demonstrate that HAase and the soft framework significantly enhance the penetration ability of SMONs-HAase-Ce6 (as illustrated in Fig. 4J). Furthermore, to evaluate the cellular ROS generation capability of SMONs-HAase-Ce6, we utilized the 2’,7’,-dichlorofluorescein diacetate (DCFH-DA) probe, which undergoes oxidation by intracellular ROS to produce green fluorescent DCF. When cells were treated with different nanoparticles and laser irradiation, an apparent green fluorescence of DCF was observed, suggesting the 1O2 generation inside cells (Fig. 5A). However, it is worth noting that cells treated with SMONs-HAase-Ce6 exhibit stronger fluorescence intensity in comparison with the group of the MONs-HAase-Ce6 and SMONs-Ce6 upon laser irradiation. The relative fluorescence intensity of DCF similarly demonstrates that SMONs-HAase-Ce6 exhibits the strongest green fluorescence intensity (Fig. 5B). The flow cytometry results also demonstrated that 4T1 cells treated with SMONs-HAase-Ce6 exhibited the highest ROS levels (Fig. 5C and S5). Thereafter, the antitumor ability of SMONs-HAase-Ce6 in vitro was investigated. The cytotoxicity of SMONs-HAase-Ce6 against 4T1 and MDA-MB-231 cells was evaluated by a standard CCK-8 assay. As shown in Fig. 5E and F, concentration-dependent cytotoxicity in the presence of laser irradiation was observed. When the concentration of Ce6 reached 3 µg·mL− 1, the nanoparticles induced significant cellular damage under laser irradiation. As shown in Fig. 5G, cells treated with SMONs-HAase-Ce6 and laser irradiation exhibited the strongest red fluorescence among all the groups, suggesting that the SMONs-HAase-Ce6 under laser irradiation had the most severe lethality to living cells. In vitro behavior of SMONs-HAase-Ce6. (A) Microscopic images showing the generation of intracellular ROS within 4T1 cell lines after incubation with Ce6, SMONs-Ce6, MONs-HAase-Ce6, and SMONs-HAase-Ce6, captured via confocal microscopy. (B) Quantitative analysis of ROS fluorescence intensity. (C) Flow cytometry results for ROS detection inside 4T1 cells treated with SMONs-HAase-Ce6 following a 660 nm laser irradiation (1 W·cm− 2, 3 min). PBS(-): PBS without laser. (D) Schematic representation of the anticancer effects exerted by Ce6, MONs-HAase-Ce6, SMONs-Ce6, and SMONs-HAase-Ce6 on various cancer cells. (E-F) Viability of 4T1 and MDA-MB-231 cells after 24-hour co-incubation with varying concentrations of Ce6, SMONs-Ce6, MONs-HAase-Ce6, followed by a 660 nm laser irradiation (1 W·cm− 2, 3 min). (G) Live/dead staining results of 4T1 tumor cells subjected to different treatments and laser exposure. (H) Colony formation assay for 4T1 cells treated with PBS, PBS + Laser, Ce6 + Laser, MONs-HAase-Ce6 + Laser, SMONs-Ce6 + Laser, and SMONs-HAase-Ce6 + Laser. (I) Flow cytometry analysis of 4T1 tumor cells under different treatment conditions following laser application Subsequently, colony formation assays revealed a significant reduction in colony formation in the SMONs-HAase-Ce6 group compared to the controls, indicating its superior capability in inhibiting cell proliferation and viability (Fig. 5H). Furthermore, to investigate the apoptotic effect of various drug treatments on 4T1 cells, an Annexin V-FITC and propidium iodide (PI) dual staining assay was employed. The findings indicated that the apoptotic rate of 4T1 cells subjected to treatment with SMONs-HAase-Ce6 was significantly higher, reaching 48.4%, which is approximately 1.5-fold greater than the apoptotic rates observed in cells treated with MONs-HAase-Ce6 (30.5%) and SMONs-Ce6 NPs (23.5%). These results highlight the enhanced apoptotic potential of SMONs-HAase-Ce6 compared to other treatments, underscoring its efficacy in inducing apoptosis in 4T1 cells (Fig. 5I). All the aforementioned results demonstrate that, compared to the rigid MONs-HAase-Ce6 and the HAase-unmodified SMONs-Ce6, SMONs-HAase-Ce6 exerts the most severe cytotoxic effect on tumor cells under 660 nm laser irradiation. Then, the in vivo photodynamic therapy (PDT) efficacy was appraised utilizing 4T1 tumor-bearing mice. When the tumor volume reached 150–200 mm3 after 10 days, the mice were randomly divided into 4 groups and intravenously injected with different materials (PBS, SMONs-Ce6, MONs-HAase-Ce6, and SMONs-HAase-Ce6, and then underwent 660 nm laser irradiation for PDT 12 h after injection (Fig. 6A). The tumor volume and body weight of mice were observed and recorded for 14 days. As shown in Fig. 6B, there was no significant change in the body weight of mice in each group, indicating that there was no significant systemic toxicity in each treatment group. By the 14th day, post sacrificing the mice and evaluating tumor masses, it was apparent that the mice subjected to SMONs-HAase-Ce6 treatment exhibited the lightest tumor masses. More precisely, the tumors in the SMONs-HAase-Ce6 group weighed roughly 60% of those in the SMONs-Ce6 group and nearly 56% of the MONs-HAase-Ce6 group, as indicated in Fig. 6C. As illustrated in Fig. 6D-E, the tumor volumes associated with the SMONs-Ce6, MONs-HAase-Ce6, and SMONs-HAase-Ce6 groups exhibit significant reductions compared to the PBS control. This underscores the potential of PDT in curbing tumor growth. Delving into the specifics, while the PBS control group manifested a considerable tumor volume (1232.7 mm²), the SMONs-HAase-Ce6 group displayed a volume that was significantly reduced, nearly half of that observed in the MONs-HAase-Ce6 group and approaching a mere 40% of the SMONs-Ce6 group’s measurements. Clearly, the performance of SMONs-HAase-Ce6 surpasses that of both the stiff MONs-HAase-Ce6 and HAase-unmodified SMONs-Ce6, suggesting a profound impact of the HAase modification. This elevated anti-tumor response of SMONs-HAase-Ce6 can be attributed to its enhanced penetration depth. The individual tumor volume data for the four distinct treatment approaches are depicted in Fig. 6F-J. The PDT effectiveness. (A) The cartoon treatment schedule for in vivo PDT therapy. (B) Changes of the body weight fluctuations in mice subjected to diverse treatments. (C) The tumor mass and the tumor size (D) following various treatments, along with (E) the image of the tumors. (F-J) represent the tumor growth trajectories, monitored bi-daily (n ≥ 5). (K) displays H&E-stained tumor tissue cross-sections from each group 24 h post-irradiation, magnified fourfold, with scale bars representing 100 μm and 30 μm. Statistical significance is indicated with ***P < 0.001 The results consistently revealed that among these treatment groups, the SMONs-HAase-Ce6 group exhibited the most substantial decrease in tumor volume, indicating its superior efficacy in inhibiting tumor growth. The anti-tumor activity was further assessed 24 h post-irradiation via H&E staining of tumor histological sections. Remarkably, H&E images revealed pronounced necrosis in tissues from the SMONs-HAase-Ce6-treated mice, suggesting superior therapeutic outcomes with the soft photodynamic nanoplatforms when juxtaposed against SMONs-Ce6 and MONs-HAase-Ce6 groups (Fig. 6K). Collectively, these findings underscore the enhanced tumor suppressive efficiency rendered by the soft mesoporous nano platform with hyaluronidase modification. To investigate the transcriptional programs of SMONs-HAase-Ce6, we performed RNA sequencing (RNA-seq) on PBS samples (C, n = 6) and SMONs-HAase-Ce6 samples (T, n = 10). Principal component analysis (PCA) illustrated the significant differences between SMONs-HAase-Ce6 and PBS groups (Fig. 7A), and also verified by gene expression pattern cluster analysis (Fig. 7B). Next, we identified differentially expressed genes (DEGs) by the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and Gene Ontology (GO) enrichment analysis and obtained 2,517 up-regulated as well as 1,110 down-regulated DEGs (Fig. 7C), which exhibited good consistency among different samples in the SMONs-HAase-Ce6 and PBS groups (Fig. 7D). Then pathway enrichment was performed, revealing dysfunctional biological processes such as extracellular matrix structural constituent, cell chemotaxis, ECM-receptor interaction and glutathione metabolism (Fig. 7E), suggesting the ECM and metabolism-related effect of SMONs-HAase-Ce6. To further explore the exact influence in detail, we carried out gene set enrichment analysis (GSEA) and discovered the up-regulated degradation of the extracellular matrix, as well as down-regulated TCA cycle and ATP biosynthetic process, which suggests the degradation of the Extracellular Matrix and impaired mitochondrial function (Fig. 7F). RNA-seq analysis of DEGs between SMONs-HAase-Ce6 + Laser and PBS. (A) Principal component analysis (PCA) of Smons-HAase-Ce6 and PBS samples. (B) Heatmap showing the correlation among different samples. (C) Volcano plot showing the DEGs between SMONs-HAase-Ce6 and PBS groups. The numbers of up-/down-regulated DEGs were listed at the top. (D) Heatmap showing the relative expression levels of DEGs among different samples. (E) Bar plot showing the enriched pathways based on DEGs of SMONs-HAase-Ce6 and PBS groups. (F) GSEA plot showing the enrichment scores of several pathways in SMONs-HAase-Ce6 group compared to PBS group Finally, the in vivo toxicity of SMONs-HAase-Ce6 was further assessed by investigating the blood physiological and biochemical parameters of mice treated with SMONs-HAase-Ce6, MONs-HAase-Ce6, and SMONs-Ce6. No significant differences were observed between the normal PBS group and the test groups (Fig. S6A–I), indicating that intravenous injection of MONs-HAase-Ce6, SMONs-Ce6, and SMONs-HAase-Ce6 did not lead to any liver or kidney injury. Additionally, histopathological analysis using H&E staining of major organs (heart, liver, spleen, lung, kidney) revealed no apparent signs of inflammation, damage, or necrosis (Fig. S6J). Conclusion In conclusion, this study presents an innovative dual-modal strategy leveraging soft organosilica nanocapsules (SMONs) modified with HAase to overcome the physical barriers of the tumor microenvironment, thereby significantly enhancing the efficacy of PDT in cancer treatment. The intrinsic softness of SMONs and the enzymatic activity of HAase-functionalization synergistically facilitate deeper tumor penetration and augmented cellular internalization. Notably, the encapsulation of Ce6 within these SMONs-HAase further amplifies the therapeutic outcomes by generating elevated levels of ROS upon laser irradiation, thereby inducing substantial cytotoxic effects on cancer cells. In vitro assessments demonstrate that SMONs-HAase-Ce6 not only show enhanced cellular uptake and improved penetration depth within tumor spheroids but also significantly reduce cell viability under photodynamic conditions, highlighting their potential for efficient cancer therapy. Moreover, in vivo studies corroborate the superior therapeutic efficacy of SMONs-HAase-Ce6, showcasing a pronounced reduction in tumor growth in treated mice. In addition, the RNA sequencing of transcriptional programs confirmed the degradation of the Extracellular Matrix and impaired mitochondrial function induced by SMONs-HAase-Ce6. Collectively, our findings highlight the promise of utilizing soft nanoplatforms equipped with enzymatic functionalities for navigating the complex TME, thereby offering a potent and versatile approach for the enhancement of nanomedicine-based cancer therapies. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements W. Lu and Y. Li contributed equally to this work. We greatly appreciate the financial support from the National Natural Science Foundation of China (81971675, 21603106, and 81971681), the Natural Science Foundation of Jiangsu Province, China (BK20160017), the Natural Science Foundation of Hunan Province, China (2022JJ70092), the Innovation Platform and Talent Program of Hunan Province, China (2021SK4021), and the Rui Xin project of Hunan Provincial Maternal and Child Health Care Hospital (2023RX03). Author contributions Wei Lu (W.L.) and Yang Li (Y.L.) contributed equally to this work. They designed the study, conducted the experiments, wrote the initial draft of the manuscript, and made great contributions to the revision.Xiaojun Zhang (X.Z.) performed the statistical analysis and contributed to the interpretation of data.Ning Wang (N.W.) conducted the experiments and wrote part of the initial draft.Dong Chen (D.C.), and Xuzhi Shi (X.S.) synthesized the organosilica nanocapsules and contributed to the methodology section.Yatong Zhao (Y.Z.) and Guang Li (G.L.) assisted in the in vitro experiments.Xiaobo Ma (X.M.) and Xiaodan Su (X.S.) contributed to the in vivo efficacy studies.Feng Wang (F.W.), Chuqiang Shu (C.S.), and Kun Chen (K.C.) provided critical revisions of the manuscript for important intellectual content.All authors reviewed and approved the final manuscript. Data availability No datasets were generated or analysed during the current study. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Wei Lu and Yang Li contributed equally to this work. Contributor Information Feng Wang, Email: fengwangcn@hotmail.com. Chuqiang Shu, Email: chqshu@hotmail.com. Kun Chen, Email: iamkchen@163.com. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement No datasets were generated or analysed during the current study.